Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease
Authors:
- 25 November 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 49 (4) , 1123-1134
Abstract
Background: Bapineuzumab, an anti-amyloid-β monoclonal antibody, was evaluated in two placebo-controlled trials in APOE * ɛ 4 carriers and noncarriers, respectively, with Alzheimer’s disease. Objectives: A volumetric magnetic resonance imaging substudy was performed to determine if bapineuzumab altered brain volume rate of change. Methods: Bapineuzumab dosages included 0.5 mg/kg in carriers and 0.5 or 1.0 mg/kg in noncarriers, every 13 weeks for 78 weeks. Volumetric outcomes included annualized brain, ventricular, and mean hippocampal boundary shift integrals (BBSI; VBSI; HBSI) up to Week 71. Treatment differences were estimated using mixed models for repeated measures. Results: For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0 mg/kg bapineuzumab had greater increases in these measures. Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5 mg/kg in carriers and 1.0 mg/kg (but not 0.5 mg/kg) in noncarriers. Conclusions: Bapineuzumab produced an increase in ventricular volume compared with placebo. Etiology for this increase is unclear but may be related to amyloid-β clearance or its consequences.Keywords
This publication has 36 references indexed in Scilit:
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseNew England Journal of Medicine, 2014
- Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic interventionInternational Psychogeriatrics, 2012
- Deciphering Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- MRI correlates of neurofibrillary tangle pathology at autopsyNeurology, 2008
- Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCINeurobiology of Aging, 2008
- Volumetric MRI and cognitive measures in Alzheimer diseaseJournal of Neurology, 2008
- Forecasting the global burden of Alzheimer's diseaseAlzheimer's & Dementia, 2007